This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Astellas Pharma, Inc.
Drug Names(s): MucoRice
MucoRice is a rice-based oral vaccine expressing cholera toxin B subunit (CTB) in the intrinsic storage protein of rice using genetic engineering. Cholera toxin consists of 2 types of subunits, CTA (cholera toxin A subunit) is toxic, and CTB pentamer adheres to epithelial cells and delivers CTA into the cell.CTB has a high level of amino acid identity to the enterotoxigenic E. coli (ETEC) heat-labile toxin B-subunit.
Cholera vaccines used in developing countries require a cold chain and are ineffective against ETEC. MucoRice is stable at room temperature, easily produced, and targets both V. cholerae and ETEC. MucoRice is therefore expected to meet the unmet medical needs of existing cholera vaccines.
Astellas and University of Tokyo
In June 2016, the Institute of Medical Science at the University of Tokyo (IMSUT) and Astellas Pharma announced that they have signed a new collaborative development agreement on the rice-based oral vaccine MucoRice-CTB (MucoRice) against cholera and enterotoxigenic Escherichia coli (E coli) caused diarrheal diseases.Under the contract, IMSUT provides clinical trial materials and trial data, etc. which are necessary for the Phase I and Phase II trials of MucoRice for cholera and enterotoxigenic E coli., and Astellas is responsible for conducting and managing the clinical trials. Through the collaborative development, IMSUT and Astellas will develop vaccines against infectious diseases affecting developing countries
Partners: University of Tokyo
Additional information available to subscribers only: